Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 9:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Thalomid Clear all
Completed Phase 2 Interventional

Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant

NCT00003894
View directory record Official record
Conditions
Graft Versus Host Disease, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
thalidomide
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
3 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
10
States / cities
Little Rock, Arkansas • Kansas City, Kansas • New Orleans, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2011 · Synced Sep 24, 2026, 9:36 PM EDT
Completed Phase 2 Interventional

Thalidomide in Treating Patients With Myelodysplastic Syndrome

NCT00015990
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Secondary Myelodysplastic Syndromes
Interventions
thalidomide, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Sep 24, 2026, 9:36 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma

NCT00098475
View directory record Official record
Conditions
DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma
Interventions
Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide, Thalidomide
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2026
U.S. locations
138
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 115 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 24, 2026, 9:36 PM EDT
Completed Phase 2 Interventional Results available

Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)

NCT00307294
View directory record Official record
Conditions
Prostate Cancer
Interventions
Thalidomide, Doxil
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Sep 24, 2026, 9:36 PM EDT
Completed Phase 2 Interventional

Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00047294
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
celecoxib, temozolomide, thalidomide, adjuvant therapy
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
4
States / cities
Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Sep 24, 2026, 9:36 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients

NCT00113919
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Busulfan
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2017 · Synced Sep 24, 2026, 9:36 PM EDT
Terminated Phase 2 Interventional Results available

PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer

NCT00090870
View directory record Official record
Conditions
Kidney Cancer
Interventions
PEG-interferon alfa-2b, GM-CSF, thalidomide
Biological · Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Sep 24, 2026, 9:36 PM EDT
Completed Phase 2 Interventional

Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant

NCT00182663
View directory record Official record
Conditions
Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
clarithromycin, thalidomide, dexamethasone
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
14 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Sep 24, 2026, 9:36 PM EDT
Completed Phase 3 Interventional

A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes

NCT00050843
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
thalidomide
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
38
States / cities
La Jolla, California • Palm Springs, California • Rancho Mirage, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 24, 2026, 9:36 PM EDT
Not listed Phase 2 Interventional

Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma

NCT00438841
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
bortezomib, cyclophosphamide, dexamethasone, thalidomide
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
10
States / cities
Berkeley, California • Los Angeles, California • Palm Springs, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Sep 24, 2026, 9:36 PM EDT
Completed Phase 2 Interventional

Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma

NCT00008242
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
dexamethasone, doxorubicin hydrochloride, thalidomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Sep 24, 2026, 9:36 PM EDT
Completed Not applicable Interventional

Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome

NCT00002157
View directory record Official record
Conditions
HIV Infections, HIV Wasting Syndrome
Interventions
Thalidomide
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Warren Township, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 24, 2026, 9:36 PM EDT
Completed Phase 1 Interventional

A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection

NCT00000812
View directory record Official record
Conditions
HIV Infections
Interventions
Thalidomide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
6
States / cities
Aurora, Colorado • Minneapolis, Minnesota • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 24, 2026, 9:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant

NCT00089453
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dexamethasone, Cyclophosphamide, Melphalan, Fludarabine, Bortezomide, Leukapheresis, Interleukin, Infusion #1, Leukapheresis #2, Infusion #2, Auto Graft
Drug · Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Sep 24, 2026, 9:36 PM EDT
Completed Phase 2 Interventional

Thalidomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00053300
View directory record Official record
Conditions
Lung Cancer
Interventions
thalidomide, adjuvant therapy
Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
2
States / cities
Detroit, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 9, 2010 · Synced Sep 24, 2026, 9:36 PM EDT
Completed Phase 1 Interventional

Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

NCT00052416
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
thalidomide
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
2
States / cities
Boston, Massachusetts • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Sep 24, 2026, 9:36 PM EDT
Completed Phase 2 Interventional

Dexamethasone or Dexamethasone in Combination With Thalidomide as Salvage Therapy

NCT00083902
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Thalidomide, Dexamethasone
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2010 · Synced Sep 24, 2026, 9:36 PM EDT
Terminated Phase 1Phase 2 Interventional

Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL

NCT03379051
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Interventions
Venetoclax, Umbralisib, Ublituximab, Lenalidomide
Drug · Biological
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Sep 24, 2026, 9:36 PM EDT
Completed Phase 2 Interventional

UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma

NCT00113932
View directory record Official record
Conditions
Multiple Myeloma
Interventions
High-Dose Density Therapy
Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2011 · Synced Sep 24, 2026, 9:36 PM EDT
Terminated Phase 1 Interventional

Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis

NCT00418132
View directory record Official record
Conditions
Scleroderma, Systemic
Interventions
Thalidomide, Placebo thalidomide
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Sep 24, 2026, 9:36 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer

NCT00450008
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
GM-CSF, thalidomide, docetaxel
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 24, 2026, 9:36 PM EDT
Completed Phase 2 Interventional

Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma

NCT00072163
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Melanoma, Tumors Metastatic to Brain
Interventions
temozolomide, thalidomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Sep 24, 2026, 9:36 PM EDT
Terminated Phase 2 Interventional Results available

Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC)

NCT00953615
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Thalidomide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 72 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 26, 2012 · Synced Sep 24, 2026, 9:36 PM EDT
Completed Phase 2 Interventional Results available

Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas

NCT00412542
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioma
Interventions
Thalidomide, CPT-11, MRI Scan, Quantitative Sensory Tests (QST)
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Sep 24, 2026, 9:36 PM EDT